Clinical Trial Detail

NCT ID NCT03812393
Title Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast (FACT-2)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors West Cancer Center
Indications

triple-receptor negative breast cancer

Therapies

Carboplatin + Neratinib + Paclitaxel

Neratinib

Age Groups: adult senior

No variant requirements are available.